Gene promoter methylation and its potential relevance in early prostate cancer diagnosis

Pathobiology

Volumn 77, Issue 5, 2010, Pages 260-266

  Steiner, Isabel ^a   Jung, Klaus ^a   Schatz, Philipp ^b   Horns, Torsten ^b   Wittschieber, Daniel ^a   Lein, Michael ^a   Dietel, Manfred ^a   Erbersdobler, Andreas ^c  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b EPIGENOMICS AG   (Germany)

^c UNIVERSITY OF ROSTOCK   (Germany)

Author keywords

Field effect; GSTP1; Promoter hypermethylation; Prostate cancer; RAR 2

Indexed keywords

APC PROTEIN; FORMALDEHYDE; GLUTATHIONE TRANSFERASE P1; PARAFFIN; PROSTATE SPECIFIC ANTIGEN; RETINOIC ACID RECEPTOR BETA; RETINOIC ACID RECEPTOR BETA2; TRANSCRIPTION FACTOR PITX2; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER GRADING; CANCER RISK; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATIONAL STUDY; DNA EXTRACTION; DNA METHYLATION; EARLY DIAGNOSIS; GLEASON SCORE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; PROSTATECTOMY; PROSTATIC INTRAEPITHELIAL NEOPLASIA; TUMOR LOCALIZATION;

ADENOMATOUS POLYPOSIS COLI PROTEIN; AGED; DNA METHYLATION; EARLY DETECTION OF CANCER; GLUTATHIONE S-TRANSFERASE PI; HOMEODOMAIN PROTEINS; HUMANS; MALE; MIDDLE AGED; PROMOTER REGIONS, GENETIC; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROSTATIC NEOPLASMS; RECEPTORS, RETINOIC ACID; TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 78649861752     PISSN: 10152008     EISSN: None     Source Type: Journal    
DOI: 10.1159/000318017     Document Type: Article

References (30)

1. Neal DE, Donovan JL: Prostate cancer: to screen or not to screen? Lancet Oncol 2000;1:17-24.
2. Catalona WJ, Smith DS, Ratliff TL, Dodds KM, Coplen DE, Yuan JJ, Petros JA, Andriole GL: Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 1991;324:1156-1161.
3. Catalona WJ, Partin AW, Slawin KM, Naughton CK, Brawer MK, Flanigan RC, Richie JP, Patel A, Walsh PC, Scardino PT, Lange PH, deKernion JB, Southwick PC, Loveland KG, Parson RE, Gasior GH: Percentage of free PSA in black versus white men for detection and staging of prostate cancer: a prospective multicenter clinical trial. Urology 2000;55:372-376.
4. Jones PA, Baylin SB: The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002;3:415-428.
5. Jones PA, Laird PW: Cancer epigenetics comes of age. Nat Genet 1999;21:163-167.
6. Herman JG, Baylin SB: Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003;349:2042-2054.
7. Lin X, Tascilar M, Lee WH, Vles WJ, Lee BH, Veeraswamy R, Asgari K, Freije D, van RB, Gage WR, Bova GS, Isaacs WB, Brooks JD, Deweese TL, De Marzo AM, Nelson WG: GSTP1 CpG island hypermethylation is responsible for the absence of GSTP1 expression in human prostate cancer cells. Am J Pathol 2001;159:1815-1826.
8. Lee WH, Morton RA, Epstein JI, Brooks JD, Campbell PA, Bova GS, Hsieh WS, Isaacs WB, Nelson WG: Cytidine methylation of regulatory sequences near the pi-class glutathione S-transferase gene accompanies human prostatic carcinogenesis. Proc Natl Acad Sci USA 1994;91:11733-11737.
9. Nelson WG, De Marzo AM, Deweese TL, Lin X, Brooks JD, Putzi MJ, Nelson CP, Groopman JD, Kensler TW: Preneoplastic prostate lesions: an opportunity for prostate cancer prevention. Ann NY Acad Sci 2001;952:135-144.
10. Jeronimo C, Henrique R, Hoque MO, Ribeiro FR, Oliveira J, Fonseca D, Teixeira MR, Lopes C, Sidransky D: Quantitative RARbeta2 hypermethylation: a promising prostate cancer marker. Clin Cancer Res 2004;10:4010-4014.
11. Kang GH, Lee S, Lee HJ, Hwang KS: Aberrant CpG island hypermethylation of multiple genes in prostate cancer and prostatic intraepithelial neoplasia. J Pathol 2004;202:233-240.
12. Esteller M, Corn PG, Baylin SB, Herman JG: A gene hypermethylation profile of human cancer. Cancer Res 2001;61:3225-3229.
13. Henrique R, Ribeiro FR, Fonseca D, Hoque MO, Carvalho AL, Costa VL, Pinto M, Oliveira J, Teixeira MR, Sidransky D, Jeronimo C: High promoter methylation levels of APC predict poor prognosis in sextant biopsies from prostate cancer patients. Clin Cancer Res 2007;13:6122-6129.
14. Weiss G, Cottrell S, Distler J, Schatz P, Kristiansen G, Ittmann M, Haefliger C, Lesche R, Hartmann A, Corman J, Wheeler T: DNA methylation of the PITX2 gene promoter region is a strong independent prognostic marker of biochemical recurrence in patients with prostate cancer after radical prostatectomy. J Urol 2009;181:1678-1685.
15. Slaughter DP, Southwick HW, Smejkal W: Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin. Cancer 1953;6:963-968.
16. Vauthey JN, Walsh GL, Vlastos G, Lauwers GY: Importance of field cancerisation in clinical oncology. Lancet Oncol 2000;1:15-16.
17. Hanson JA, Gillespie JW, Grover A, Tangrea MA, Chuaqui RF, Emmert-Buck MR, Tangrea JA, Libutti SK, Linehan WM, Woodson KG: Gene promoter methylation in prostate tumor-associated stromal cells. J Natl Cancer Inst 2006;98:255-261.
18. Mehrotra J, Varde S, Wang H, Chiu H, Vargo J, Gray K, Nagle RB, Neri JR, Mazumder A: Quantitative, spatial resolution of the epigenetic field effect in prostate cancer. Prostate 2008;68:152-160.
19. Distler J: Quantification of methylated DNA by HeavyMethyl duplex PCR. Methods Mol Biol 2009;507:339-346.
20. Harden SV, Tokumaru Y, Westra WH, Goodman S, Ahrendt SA, Yang SC, Sidransky D: Gene promoter hypermethylation in tumors and lymph nodes of stage I lung cancer patients. Clin Cancer Res 2003;9:1370-1375.
21. Eads CA, Danenberg KD, Kawakami K, Saltz LB, Blake C, Shibata D, Danenberg PV, Laird PW: MethyLight: a high-throughput assay to measure DNA methylation. Nucleic Acids Res 2000;28: E32.
22. Yegnasubramanian S, Kowalski J, Gonzalgo ML, Zahurak M, Piantadosi S, Walsh PC, Bova GS, De Marzo AM, Isaacs WB, Nelson WG: Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Res 2004;64:1975-1986.
23. Bastian PJ, Ellinger J, Wellmann A, Wernert N, Heukamp LC, Muller SC, von Ruecker A: Diagnostic and prognostic information in prostate cancer with the help of a small set of hypermethylated gene loci. Clin Cancer Res 2005;11:4097-4106.
24. Tokumaru Y, Harden SV, Sun DI, Yamashita K, Epstein JI, Sidransky D: Optimal use of a panel of methylation markers with GSTP1 hypermethylation in the diagnosis of prostate adenocarcinoma. Clin Cancer Res 2004;10:5518-5522.
25. Nakayama M, Bennett CJ, Hicks JL, Epstein JI, Platz EA, Nelson WG, De Marzo AM: Hypermethylation of the human glutathione S-transferase-pi gene (GSTP1) CpG island is present in a subset of proliferative inflammatory atrophy lesions but not in normal or hyperplastic epithelium of the prostate: a detailed study using laser-capture microdissection. Am J Pathol 2003;163:923-933.
26. Goessl C, Krause H, Muller M, Heicappell R, Schrader M, Sachsinger J, Miller K: Fluorescent methylation-specific polymerase chain reaction for DNA-based detection of prostate cancer in bodily fluids. Cancer Res 2000;60:5941-5945.
27. Rabiau N, Thiam MO, Satih S, Guy L, Kemeny JL, Boiteux JP, Fontana L, Bignon YJ, Bernard-Gallon D: Methylation analysis of BRCA1, RASSF1, GSTP1 and EPHB2 promoters in prostate biopsies according to different degrees of malignancy. In Vivo 2009;23:387-391.
28. Zhou M, Tokumaru Y, Sidransky D, Epstein JI: Quantitative GSTP1 methylation levels correlate with Gleason grade and tumor volume in prostate needle biopsies. J Urol 2004;171:2195-2198.
29. Richiardi L, Fiano V, Vizzini L, De ML, Delsedime L, Akre O, Tos AG, Merletti F: Promoter methylation in APC, RUNX3, and GSTP1 and mortality in prostate cancer patients. J Clin Oncol 2009;27:3161-3168.
30. Kwabi-Addo B, Chung W, Shen L, Ittmann M, Wheeler T, Jelinek J, Issa JP: Age-related DNA methylation changes in normal human prostate tissues. Clin Cancer Res 2007;13:3796-3802.